Compare Amylx Pharmaceuticals Inc (AMLX) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Canadian Natural Resources Ltd. — how do they compare? Amylx Pharmaceuticals Inc trades at $24.05 (market cap $2.64B), while Canadian Natural Resources Ltd. trades at $47.71 (market cap $98.11B). The key difference: Canadian Natural Resources Ltd. is far larger — about 37.2× Amylx Pharmaceuticals Inc's market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CNQ | |
|---|---|---|
Market Cap | $2.64B | $98.11B |
Sector | Health | Energy |
52-Week High | $24.19 | $50.55 |
52-Week Low | $7.82 | $29.31 |
Enterprise Value | $2.39B | $108.54B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
CNQ trades at $47.25, up 3.82% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.53, exceeding expectations, and maintains robust profitability with a net income margin of 22.87%. Recent news highlights record production and a quarterly dividend of $0.63, reinforcing financial strength.
Outlook is positive due to low valuation multiples, consistent dividend payouts, and upward earnings revisions. Key risks include oil price volatility and rising debt levels. Analyst consensus is strongly bullish with 75% buy ratings, supporting potential upside if operational momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
